Pay in 4 interest-free payments of $7.33 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Summary: Retatrutide is an investigational triple receptor agonist (GLP-1, GIP, and glucagon) that, based on Phase 2 trial data, produces significant appetite suppression and progressive weight loss, alongside gastrointestinal side effects that are most prominent during dose escalation
Protection from moisture represents a particularly critical storage requirement for Tirzepatide ODT due to the hygroscopic nature of oral disintegrating tablet formulations
Community & Anecdotal Results Context Since retatrutide isn't FDA-approved, real-world data is limited to compounded formulations and gray-market sources
Repeat daily, or as directed by prescriber
US$ 24.79
US$ 21.44
US$ 25.53
US$ 28.32
